pyrazinamide has been researched along with HIV Coinfection in 107 studies
pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of the study was to document the pharmacokinetics of the first-line anti-TB agents in children <2 years of age comparing previous and revised WHO dosages of isoniazid (INH; 5 versus 10 mg/kg/day), rifampin (RMP; 10 versus 15 mg/kg/day), and pyrazinamide (PZA; 25 versus 35 mg/kg/day) and to investigate the effects of clinical covariates, including HIV coinfection, nutritional status, age, gender, and type of tuberculosis (TB), and the effect of NAT2 acetylator status." | 9.15 | Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. ( Donald, PR; Hesseling, AC; Magdorf, K; Roll, S; Rosenkranz, B; Schaaf, HS; Seddon, JA; Seifart, HI; Thee, S; Werely, CJ, 2011) |
| "We evaluated the effects of human immunodeficiency virus (HIV) disease on pharmacokinetics of antituberculosis medications by measuring concentrations of isoniazid and rifampin in blood and of pyrazinamide and ethambutol in urine." | 9.11 | Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. ( Bhagavathy, S; Gurumurthy, P; Hemanth Kumar, AK; Mahilmaran, A; Padmapriyadarsini, C; Paramesh, P; Rajasekaran, S; Ramachandran, G; Ravichandran, N; Sekar, L; Swaminathan, S; Venkatesan, P, 2004) |
| "To determine population pharmacokinetic parameters of pyrazinamide after multiple oral doses given to children and adults with tuberculosis." | 9.10 | Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis. ( Ashkin, D; Berning, SE; Bulpitt, AE; Burman, WJ; Peloquin, CA; Stambaugh, JJ; Starke, JR; Steiner, P; Zhu, M, 2002) |
| "Because of problems with adherence, toxicity, and increasing resistance associated with 6- to 12-month isoniazid regimens, an alternative short-course tuberculosis preventive regimen is needed." | 9.09 | Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O ( Barry, MA; Chaisson, RE; Coberly, J; de Lourdes Garcia, M; Gordin, F; Hafner, R; Klukowicz, AJ; Matts, JP; Miller, C; O'Brien, RJ; Schechter, M; Valdespino, JL, 2000) |
| "The meta-analysis did not demonstrate an increased risk of severe hepatoxicity in HIV-infected patients receiving tuberculosis prophylaxis with the rifampicin/pyrazinamide combination compared to the conventional 6- or 12-month isoniazid-based regimen." | 8.86 | [Use of rifampicin plus pyrazinamide for antituberculosis prophylaxis does not increase the risk of severe hepatotoxicity in HIV patients: meta-analysis of randomized controlled clinical trials]. ( Camacho, A; Castón, JJ; Gallo, M; García-Lázaro, M; Kindelán, JM; Natera, C; Pérez-Camacho, I; Rivero, A; Torre-Cisneros, J, 2010) |
| " isoniazid (INH) for the prevention of tuberculosis (TB) among persons with or without human immunodeficiency virus (HIV) infection." | 8.83 | Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis. ( Gao, XF; Li, YP; Liu, GJ; Sun, X; Wang, L; Wen, J; Xie, Y, 2006) |
| "Lopinavir-ritonavir forms the backbone of current first-line antiretroviral regimens in young HIV-infected children." | 7.88 | Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis. ( de Kock, M; Denti, P; Garcia-Prats, AJ; Hesseling, AC; McIlleron, H; Norman, J; Schaaf, HS; Tikiso, T; van der Laan, LE; Wiesner, L; Winckler, J, 2018) |
| "Rifampin (RIF) mono-resistant tuberculosis (RMR-TB) is a rare disease." | 7.85 | Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis. ( Jo, KW; Kim, WS; Lee, SD; Park, S; Shim, TS, 2017) |
| "To compare the pharmacokinetics of rifampicin (RMP), isoniazid (INH) and pyrazinamide (PZA) between HIV-infected and HIV-uninfected children with tuberculosis (TB) and correlate it with TB treatment outcome." | 7.83 | Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status. ( Agarwal, D; Banurekha, VV; Bhavani, PK; Gangadevi, NP; Kalpana, S; Kannan, T; Kumar, AK; Kumar, SR; Mathevan, G; Ramachandran, G; Ravichandran, N; Sanjeeva, GN; Sudha, V; Swaminathan, S; Venkatesh, S, 2016) |
| "Comprehensive information on the effects of cytochrome P450 2B6 (CYP2B6) polymorphisms, clinical factors, and drug-drug interactions on efavirenz concentrations in HIV/tuberculosis-coinfected (HIV/TB) patients is unavailable." | 7.79 | Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients. ( Lueangniyomkul, A; Mankatitham, W; Manosuthi, S; Manosuthi, W; Nilkamhang, S; Sukasem, C; Sungkanuparph, S; Thongyen, S, 2013) |
| "In 2000, results of a multinational trial demonstrated that a 2-month course of rifampin and pyrazinamide (RZ) was as effective as isoniazid (INH) in reducing tuberculosis in human immunodeficiency virus (HIV)-infected individuals with latent tuberculosis infection (LTBI)." | 7.72 | Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons? ( Chaisson, RE; Cohn, DL; Gordin, FM; Matts, JP; O'Brien, RJ, 2004) |
| "The pharmacokinetics of pyrazinamide (PZA) in patients with human immunodeficiency virus (HIV)-related tuberculosis are incompletely characterized." | 7.72 | The clinical pharmacokinetics of pyrazinamide in HIV-infected persons with tuberculosis. ( Chirgwin, K; Hafner, R; Peloquin, CA; Perlman, DC; Rainey, PM; Remmel, RP; Rosenkranz, S; Salomon, N; Segal, Y, 2004) |
| " Patients underwent intensive pharmacokinetic sampling before and after the initiation of antiretroviral therapy, which can increase immune activation in HIV/tuberculosis." | 5.46 | Pyrazinamide clearance is impaired among HIV/tuberculosis patients with high levels of systemic immune activation. ( Bisson, GP; Gumbo, T; Modongo, C; Pasipanodya, J; Ravimohan, S; Srivastava, S; Tamuhla, N; Vinnard, C; Weissman, D; Zetola, NM, 2017) |
| "One hundred patients with pulmonary tuberculosis (65% coinfected with HIV-1) were intensively sampled to determine rifampin, isoniazid, and pyrazinamide plasma concentrations after 7 to 8 weeks of a daily quadruple-therapy regimen dosed according to World Health Organization (WHO) weight bands." | 5.43 | HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients. ( Chirehwa, M; Denti, P; McIlleron, H; Meintjes, G; Rockwood, N; Wiesner, L; Wilkinson, RJ, 2016) |
| " We included studies in children aged <18 years being treated for drug-susceptible tuberculosis with rifampicin (RIF), pyrazinamide, isoniazid, and ethambutol." | 5.41 | Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis. ( Béranger, A; Gegia, M; Linh, NN; Mirzayev, F; Mohamed, A; Nahid, P; Radtke, K; Savic, RM; Schumacher, SG; Solans, BP, 2023) |
| "The objective of this report was to study the pharmacokinetics of rifampin (RMP), isoniazid (INH), and pyrazinamide (PZA) in HIV-infected children with tuberculosis (TB) treated with a thrice-weekly anti-TB regimen in the government program in India." | 5.20 | Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India. ( Banurekha, VV; Bhavani, PK; Dayal, R; Gangadevi, NP; Kannan, T; Kumar, AK; Kumar, SR; Mathevan, G; Ramachandran, G; Ravichandran, N; Sanjeeva, GN; Sekar, L; Swaminathan, S, 2015) |
| " The aim of the study was to document the pharmacokinetics of the first-line anti-TB agents in children <2 years of age comparing previous and revised WHO dosages of isoniazid (INH; 5 versus 10 mg/kg/day), rifampin (RMP; 10 versus 15 mg/kg/day), and pyrazinamide (PZA; 25 versus 35 mg/kg/day) and to investigate the effects of clinical covariates, including HIV coinfection, nutritional status, age, gender, and type of tuberculosis (TB), and the effect of NAT2 acetylator status." | 5.15 | Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. ( Donald, PR; Hesseling, AC; Magdorf, K; Roll, S; Rosenkranz, B; Schaaf, HS; Seddon, JA; Seifart, HI; Thee, S; Werely, CJ, 2011) |
| "To compare the efficacy of an intermittent 6-month regimen (Reg6M: 2EHRZ(3)/4HR(3) [ethambutol, 1,200 mg; isoniazid, 600 mg; rifampicin, 450 or 600 mg depending on body weight <60 or > or =60 kg; and pyrazinamide, 1,500 mg for 2 mo; followed by 4 mo of isoniazid and rifampicin at the same doses]) versus a 9-month regimen (Reg9M: 2EHRZ(3)/7HR(3)) in HIV/tuberculosis (TB)." | 5.14 | Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. ( Chinnaiyan, P; Iliayas, S; Menon, PA; Narayanan, PR; Narendran, G; Padmapriyadarsini, C; Ramachandran, R; Sakthivel, R; Santhanakrishnan, R; Suhadev, M; Swaminathan, S; Venkatesan, P, 2010) |
| "We evaluated the effects of human immunodeficiency virus (HIV) disease on pharmacokinetics of antituberculosis medications by measuring concentrations of isoniazid and rifampin in blood and of pyrazinamide and ethambutol in urine." | 5.11 | Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. ( Bhagavathy, S; Gurumurthy, P; Hemanth Kumar, AK; Mahilmaran, A; Padmapriyadarsini, C; Paramesh, P; Rajasekaran, S; Ramachandran, G; Ravichandran, N; Sekar, L; Swaminathan, S; Venkatesan, P, 2004) |
| "To determine population pharmacokinetic parameters of pyrazinamide after multiple oral doses given to children and adults with tuberculosis." | 5.10 | Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis. ( Ashkin, D; Berning, SE; Bulpitt, AE; Burman, WJ; Peloquin, CA; Stambaugh, JJ; Starke, JR; Steiner, P; Zhu, M, 2002) |
| "Because of problems with adherence, toxicity, and increasing resistance associated with 6- to 12-month isoniazid regimens, an alternative short-course tuberculosis preventive regimen is needed." | 5.09 | Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O ( Barry, MA; Chaisson, RE; Coberly, J; de Lourdes Garcia, M; Gordin, F; Hafner, R; Klukowicz, AJ; Matts, JP; Miller, C; O'Brien, RJ; Schechter, M; Valdespino, JL, 2000) |
| "The meta-analysis did not demonstrate an increased risk of severe hepatoxicity in HIV-infected patients receiving tuberculosis prophylaxis with the rifampicin/pyrazinamide combination compared to the conventional 6- or 12-month isoniazid-based regimen." | 4.86 | [Use of rifampicin plus pyrazinamide for antituberculosis prophylaxis does not increase the risk of severe hepatotoxicity in HIV patients: meta-analysis of randomized controlled clinical trials]. ( Camacho, A; Castón, JJ; Gallo, M; García-Lázaro, M; Kindelán, JM; Natera, C; Pérez-Camacho, I; Rivero, A; Torre-Cisneros, J, 2010) |
| " isoniazid (INH) for the prevention of tuberculosis (TB) among persons with or without human immunodeficiency virus (HIV) infection." | 4.83 | Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis. ( Gao, XF; Li, YP; Liu, GJ; Sun, X; Wang, L; Wen, J; Xie, Y, 2006) |
| "We used nonlinear mixed-effects modeling to characterize the pharmacokinetics of rifampicin, isoniazid, and pyrazinamide, and investigated the association of human immunodeficiency virus (HIV), antiretroviral therapy (ART), drug formulation, age, and body size with their pharmacokinetics." | 4.31 | Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis. ( Aarnoutse, R; Chabala, C; Cotton, MF; Denti, P; Galileya, LT; Gibb, D; Hesseling, A; Lee, J; McIlleron, H; Njahira Mukui, I; Rabie, H; Turkova, A; Wasmann, RE; Zar, H, 2023) |
| "Pyrazinamide is a first-line drug used in the treatment of tuberculosis." | 4.02 | Factors Affecting the Pharmacokinetics of Pyrazinamide and Its Metabolites in Patients Coinfected with HIV and Implications for Individualized Dosing. ( Äbelö, A; Ashton, M; Bienvenu, E; Hoffmann, KJ; Sundell, J; Wijk, M, 2021) |
| "Lopinavir-ritonavir forms the backbone of current first-line antiretroviral regimens in young HIV-infected children." | 3.88 | Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis. ( de Kock, M; Denti, P; Garcia-Prats, AJ; Hesseling, AC; McIlleron, H; Norman, J; Schaaf, HS; Tikiso, T; van der Laan, LE; Wiesner, L; Winckler, J, 2018) |
| "Rifampin (RIF) mono-resistant tuberculosis (RMR-TB) is a rare disease." | 3.85 | Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis. ( Jo, KW; Kim, WS; Lee, SD; Park, S; Shim, TS, 2017) |
| "To compare the pharmacokinetics of rifampicin (RMP), isoniazid (INH) and pyrazinamide (PZA) between HIV-infected and HIV-uninfected children with tuberculosis (TB) and correlate it with TB treatment outcome." | 3.83 | Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status. ( Agarwal, D; Banurekha, VV; Bhavani, PK; Gangadevi, NP; Kalpana, S; Kannan, T; Kumar, AK; Kumar, SR; Mathevan, G; Ramachandran, G; Ravichandran, N; Sanjeeva, GN; Sudha, V; Swaminathan, S; Venkatesh, S, 2016) |
| "The World Health Organization recommends for tuberculosis retreatment a regimen of isoniazid (H), rifampicin (R), ethambutol (E), pyrazinamide (Z), and streptomycin (S) for 2 months, followed by H, R, E, and Z for 1 month and H, R, and E for 5 months." | 3.81 | High mortality associated with retreatment of tuberculosis in a clinic in Kampala, Uganda: a retrospective study. ( Acuña-Villaorduña, C; Ayakaka, I; Dryden-Peterson, S; Fennelly, KP; Hosford, J; Jones-López, EC; Nakubulwa, S; Okwera, A; Reilly, N; Worodria, W, 2015) |
| "Comprehensive information on the effects of cytochrome P450 2B6 (CYP2B6) polymorphisms, clinical factors, and drug-drug interactions on efavirenz concentrations in HIV/tuberculosis-coinfected (HIV/TB) patients is unavailable." | 3.79 | Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients. ( Lueangniyomkul, A; Mankatitham, W; Manosuthi, S; Manosuthi, W; Nilkamhang, S; Sukasem, C; Sungkanuparph, S; Thongyen, S, 2013) |
| "The pharmacokinetics of pyrazinamide (PZA) in patients with human immunodeficiency virus (HIV)-related tuberculosis are incompletely characterized." | 3.72 | The clinical pharmacokinetics of pyrazinamide in HIV-infected persons with tuberculosis. ( Chirgwin, K; Hafner, R; Peloquin, CA; Perlman, DC; Rainey, PM; Remmel, RP; Rosenkranz, S; Salomon, N; Segal, Y, 2004) |
| "In 2000, results of a multinational trial demonstrated that a 2-month course of rifampin and pyrazinamide (RZ) was as effective as isoniazid (INH) in reducing tuberculosis in human immunodeficiency virus (HIV)-infected individuals with latent tuberculosis infection (LTBI)." | 3.72 | Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons? ( Chaisson, RE; Cohn, DL; Gordin, FM; Matts, JP; O'Brien, RJ, 2004) |
| " Peak drug exposure to isoniazid was lower in patients with diarrhea." | 3.69 | Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. ( Cameron, DW; Gallicano, K; Garber, G; Oliveras, L; Rachlis, A; Sahai, J; Seguin, I; Swick, L; Tailor, S; Walker, S, 1997) |
| "There are limited pharmacokinetic data for use of the first-line antituberculosis drugs during infancy (<12 months of age), when drug disposition may differ." | 2.82 | Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines. ( Bekker, A; Donald, PR; Draper, HR; Hesseling, AC; McIlleron, HM; Murray, S; Schaaf, HS; van der Laan, L; Wiesner, L, 2016) |
| " Nonlinear mixed-effects modeling found that influential covariates for the pharmacokinetics were weight, sex, and a 30% increased bioavailability among heterozygous carriers of SLCO1B1 rs1104581 (previously associated with low rifampin concentrations)." | 2.82 | Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis. ( Egan, D; Hennig, S; Kellerman, T; McIlleron, H; Naiker, S; Owen, A; Pym, A; Reddy, T; Wiesner, L, 2016) |
| " A total of 47 Malawian adults underwent rich pharmacokinetic sampling at 0, 0." | 2.80 | Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi. ( Davies, G; Dimba, A; Dzinjalamala, FK; Molyneux, EM; Molyneux, ME; van Oosterhout, JJ; Ward, S; Waterhouse, D; Zijlstra, EE, 2015) |
| " The pharmacokinetic parameters of rifampin, isoniazid, ethambutol, and pyrazinamide were determined for each patient." | 2.80 | Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. ( Chigutsa, E; Gumbo, T; McIlleron, H; Pasipanodya, JG; Sirgel, FA; Smith, PJ; van Helden, PD; Visser, ME, 2015) |
| " Adverse events were mostly mild and no serious adverse events or drug discontinuations were reported." | 2.78 | Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study. ( Aarnoutse, RE; Boeree, MJ; Burger, DM; Fillekes, Q; Kibiki, GS; Kisanga, ER; Kisonga, RM; Mleoh, L; Mtabho, CM; Ndaro, A; Semvua, HH; van den Boogaard, J; van der Ven, A, 2013) |
| "Tuberculosis was associated with an increased mortality (adjusted rate ratio 1." | 2.70 | Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. ( Fuchs, D; Godfrey-Faussett, P; Hosp, M; Lisse, I; Mwinga, A; Quigley, MA, 2001) |
| " Inter-individual pharmacokinetic variability and the effect of age, nutritional status, Human immunodeficiency virus (HIV) infection, acetylator genotype may need to be accounted for in striving for the dosages best suited for an individual." | 2.61 | Pharmacokinetics of First-Line Anti-Tubercular Drugs. ( Kabra, SK; Lodha, R; Mukherjee, A, 2019) |
| "This review will introduce pharmacokinetic parameters for key anti-TB drugs, as well as the indications and limitations of measuring these parameters in clinical practice." | 2.50 | Understanding pharmacokinetics to improve tuberculosis treatment outcome. ( Heysell, SK; Reynolds, J, 2014) |
| "Treatment was rifampin, isoniazide, and pyrazinamide or ethambutol." | 2.46 | Tuberculous orchiepididymitis during 1978-2003 period: review of 34 cases and role of 16S rRNA amplification. ( Baquero, F; Buitrago, LA; Burgos Revilla, J; Gómez García, I; Gómez Mampaso, E; Gómez Rodríguez, A; Molina, MR; Sampietro Crespo, A, 2010) |
| " Isoniazid, rifampin, and pyrazinamide concentration-time profiles and treatment outcome were obtained from 161 Indian children with drug-sensitive tuberculosis undergoing thrice-weekly dosing as per previous Indian pediatric guidelines." | 1.48 | Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications. ( Bhavani, PK; Dooley, KE; Gangadevi, NP; Guiastrennec, B; Gupta, A; Karlsson, MO; Kumar, AKH; Ramachandran, G; Savic, RM; Swaminathan, S, 2018) |
| " Patients underwent intensive pharmacokinetic sampling before and after the initiation of antiretroviral therapy, which can increase immune activation in HIV/tuberculosis." | 1.46 | Pyrazinamide clearance is impaired among HIV/tuberculosis patients with high levels of systemic immune activation. ( Bisson, GP; Gumbo, T; Modongo, C; Pasipanodya, J; Ravimohan, S; Srivastava, S; Tamuhla, N; Vinnard, C; Weissman, D; Zetola, NM, 2017) |
| " The aim of this analysis was to characterize factors contributing to the variability in exposure and to evaluate drug exposures using alternative doses, thus providing evidence to support revised dosing recommendations for drug-susceptible and multidrug-resistant tuberculosis (MDR-TB)." | 1.46 | Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis. ( Chirehwa, MT; Denti, P; McIlleron, H; Mthiyane, T; Onyebujoh, P; Rustomjee, R; Smith, P, 2017) |
| "One hundred patients with pulmonary tuberculosis (65% human immunodeficiency virus coinfected) were intensively sampled to determine rifampicin, isoniazid, and pyrazinamide plasma concentrations after 7-8 weeks of therapy, and PK parameters determined using nonlinear mixed-effects models." | 1.46 | Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis. ( Denti, P; Gumbo, T; Lesosky, M; McIlleron, H; Meintjes, G; Pasipanodya, JG; Rockwood, N; Sirgel, F; Wilkinson, RJ, 2017) |
| "One hundred patients with pulmonary tuberculosis (65% coinfected with HIV-1) were intensively sampled to determine rifampin, isoniazid, and pyrazinamide plasma concentrations after 7 to 8 weeks of a daily quadruple-therapy regimen dosed according to World Health Organization (WHO) weight bands." | 1.43 | HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients. ( Chirehwa, M; Denti, P; McIlleron, H; Meintjes, G; Rockwood, N; Wiesner, L; Wilkinson, RJ, 2016) |
| " Rifampicin concentrations during the dosing interval were determined by HPLC at three different timepoints: (i) after 2 weeks of TB therapy and before starting HIV therapy (T0); (ii) after 4 weeks of combined therapy (T1); and (iii) after 10 weeks of combined therapy (T2)." | 1.38 | Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso. ( Bonkoungou, V; Carvalho, AC; Comelli, M; Cusato, M; Dembélé, SM; Kouanda, S; Matteelli, A; Nacanabo, R; Regazzi, M; Saleri, N; Villani, P, 2012) |
| "Independent risk factors for recurrence included: infection with a pyrazinamide mono-resistant isolate (adjusted hazard ratio, 2." | 1.37 | When tuberculosis comes back: who develops recurrent tuberculosis in california? ( Deriemer, K; Flood, JM; Pascopella, L; Watt, JP, 2011) |
| "When active tuberculosis is identified, combination therapy with isoniazid, rifampin, pyrazinamide, and ethambutol should be promptly initiated for a two-month "intensive phase," and in most cases, followed by isoniazid and a rifamycin product for a four- to seven-month "continuation phase." | 1.35 | Update on the treatment of tuberculosis. ( Inge, LD; Wilson, JW, 2008) |
| " Severe adverse reactions included rash (two), toxic hepatitis (six), Immune Reconstitution Syndrome (seven), and four deaths." | 1.32 | Efficacy and safety of Efavirenz in HIV patients on Rifampin for tuberculosis. ( Alves, CR; Badaro, R; Brites, C; Netto, EM; Oliveira, AS; Pedral-Sampaio, DB, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 20 (18.69) | 18.2507 |
| 2000's | 25 (23.36) | 29.6817 |
| 2010's | 51 (47.66) | 24.3611 |
| 2020's | 11 (10.28) | 2.80 |
| Authors | Studies |
|---|---|
| Nardotto, GHB | 1 |
| Bollela, VR | 1 |
| Rocha, A | 1 |
| Della Pasqua, O | 1 |
| Lanchote, VL | 1 |
| Anderson, G | 1 |
| Vinnard, C | 2 |
| Porter, M | 1 |
| Choshi, P | 1 |
| Pedretti, S | 1 |
| Chimbetete, T | 1 |
| Smith, R | 1 |
| Meintjes, G | 5 |
| Phillips, E | 1 |
| Lehloenya, R | 1 |
| Peter, J | 1 |
| Jones, AJ | 1 |
| Mathad, JS | 1 |
| Dooley, KE | 2 |
| Eke, AC | 1 |
| Solans, BP | 1 |
| Béranger, A | 1 |
| Radtke, K | 1 |
| Mohamed, A | 1 |
| Mirzayev, F | 1 |
| Gegia, M | 1 |
| Linh, NN | 1 |
| Schumacher, SG | 1 |
| Nahid, P | 1 |
| Savic, RM | 2 |
| Galileya, LT | 1 |
| Wasmann, RE | 1 |
| Chabala, C | 1 |
| Rabie, H | 1 |
| Lee, J | 1 |
| Njahira Mukui, I | 1 |
| Hesseling, A | 1 |
| Zar, H | 1 |
| Aarnoutse, R | 1 |
| Turkova, A | 1 |
| Gibb, D | 1 |
| Cotton, MF | 2 |
| McIlleron, H | 10 |
| Denti, P | 7 |
| Yang, H | 1 |
| Antwi, S | 1 |
| Maranchick, N | 1 |
| Dompreh, A | 1 |
| Amissah, AK | 1 |
| Sly-Moore, E | 1 |
| Martyn-Dickens, C | 1 |
| Opoku, T | 1 |
| Enimil, A | 1 |
| Bosomtwe, D | 1 |
| Ojewale, O | 1 |
| Sarfo, AD | 1 |
| Appiah, AF | 1 |
| Kusi-Amponsah, I | 1 |
| Dong, SK | 1 |
| Osei Kuffour, B | 1 |
| Morgan, R | 1 |
| Alshaer, MH | 1 |
| Peloquin, CA | 6 |
| Kwara, A | 1 |
| Schutz, C | 1 |
| Chirehwa, M | 2 |
| Barr, D | 1 |
| Ward, A | 1 |
| Janssen, S | 1 |
| Burton, R | 1 |
| Wilkinson, RJ | 3 |
| Shey, M | 1 |
| Wiesner, L | 5 |
| Maartens, G | 2 |
| Xiao, K | 1 |
| Zhong, L | 1 |
| Ignatius, EH | 1 |
| Swindells, S | 1 |
| Sundell, J | 1 |
| Wijk, M | 1 |
| Bienvenu, E | 1 |
| Äbelö, A | 1 |
| Hoffmann, KJ | 1 |
| Ashton, M | 1 |
| Omonge, E | 1 |
| Otieno, F | 1 |
| Kubo, M | 1 |
| Shiruli, B | 1 |
| Chirehwa, MT | 1 |
| Rustomjee, R | 3 |
| Mthiyane, T | 2 |
| Onyebujoh, P | 1 |
| Smith, P | 2 |
| Sekaggya-Wiltshire, C | 1 |
| Castelnuovo, B | 1 |
| von Braun, A | 2 |
| Musaazi, J | 1 |
| Muller, D | 2 |
| Buzibye, A | 1 |
| Gutteck, U | 2 |
| Henning, L | 2 |
| Ledergerber, B | 1 |
| Corti, N | 2 |
| Lamorde, M | 1 |
| Fehr, J | 2 |
| Kambugu, A | 1 |
| Park, S | 1 |
| Jo, KW | 1 |
| Lee, SD | 1 |
| Kim, WS | 1 |
| Shim, TS | 1 |
| Ravimohan, S | 1 |
| Tamuhla, N | 1 |
| Pasipanodya, J | 1 |
| Srivastava, S | 1 |
| Modongo, C | 1 |
| Zetola, NM | 1 |
| Weissman, D | 2 |
| Gumbo, T | 3 |
| Bisson, GP | 1 |
| van der Laan, LE | 1 |
| Garcia-Prats, AJ | 1 |
| Schaaf, HS | 4 |
| Tikiso, T | 1 |
| de Kock, M | 1 |
| Winckler, J | 1 |
| Norman, J | 1 |
| Hesseling, AC | 3 |
| Wondale, B | 1 |
| Medihn, G | 1 |
| Teklu, T | 1 |
| Mersha, W | 1 |
| Tamirat, M | 1 |
| Ameni, G | 1 |
| Guiastrennec, B | 1 |
| Ramachandran, G | 4 |
| Karlsson, MO | 1 |
| Kumar, AKH | 1 |
| Bhavani, PK | 3 |
| Gangadevi, NP | 3 |
| Swaminathan, S | 6 |
| Gupta, A | 1 |
| Nansumba, M | 1 |
| Kumbakumba, E | 1 |
| Orikiriza, P | 1 |
| Bastard, M | 1 |
| Mwanga, JA | 1 |
| Boum, Y | 1 |
| de Beaudrap, P | 1 |
| Bonnet, M | 1 |
| Adane, K | 1 |
| Spigt, M | 1 |
| Dinant, GJ | 1 |
| Mesfin, EA | 1 |
| Beyene, D | 1 |
| Tesfaye, A | 1 |
| Admasu, A | 1 |
| Addise, D | 1 |
| Amare, M | 1 |
| Dagne, B | 1 |
| Yaregal, Z | 1 |
| Tesfaye, E | 1 |
| Tessema, B | 1 |
| Zhao, Y | 1 |
| Fox, T | 1 |
| Manning, K | 1 |
| Stewart, A | 1 |
| Tiffin, N | 1 |
| Khomo, N | 1 |
| Leslie, J | 1 |
| Boulle, A | 1 |
| Mudaly, V | 1 |
| Kock, Y | 1 |
| Wasserman, S | 1 |
| Walsh, KF | 1 |
| Souroutzidis, A | 1 |
| Vilbrun, SC | 1 |
| Peeples, M | 1 |
| Joissaint, G | 1 |
| Delva, S | 1 |
| Widmann, P | 1 |
| Royal, G | 1 |
| Pry, J | 1 |
| Bang, H | 1 |
| Pape, JW | 1 |
| Koenig, SP | 1 |
| Mukherjee, A | 2 |
| Lodha, R | 2 |
| Kabra, SK | 2 |
| Suárez, I | 1 |
| Maria Fünger, S | 1 |
| Jung, N | 1 |
| Lehmann, C | 1 |
| Reimer, RP | 1 |
| Mehrkens, D | 1 |
| Bunte, A | 1 |
| Plum, G | 1 |
| Jaspers, N | 1 |
| Schmidt, M | 1 |
| Fätkenheuer, G | 1 |
| Rybniker, J | 1 |
| O'Donnell, MR | 1 |
| Padayatchi, N | 1 |
| Kvasnovsky, C | 1 |
| Werner, L | 1 |
| Master, I | 1 |
| Horsburgh, CR | 1 |
| Smythe, W | 1 |
| Merle, CS | 1 |
| Gninafon, M | 1 |
| Lo, MB | 1 |
| Bah-Sow, O | 1 |
| Olliaro, PL | 1 |
| Lienhardt, C | 1 |
| Horton, J | 1 |
| Simonsson, US | 1 |
| Wejse, C | 1 |
| Furtado, A | 1 |
| Camara, C | 1 |
| Lüneborg-Nielsen, M | 1 |
| Sodemann, M | 1 |
| Gerstoft, J | 1 |
| Katzenstein, TL | 1 |
| Reynolds, J | 1 |
| Heysell, SK | 1 |
| Piubello, A | 1 |
| Harouna, SH | 1 |
| Souleymane, MB | 1 |
| Boukary, I | 1 |
| Morou, S | 1 |
| Daouda, M | 1 |
| Hanki, Y | 1 |
| Van Deun, A | 1 |
| Chigutsa, E | 1 |
| Pasipanodya, JG | 2 |
| Visser, ME | 2 |
| van Helden, PD | 2 |
| Smith, PJ | 2 |
| Sirgel, FA | 1 |
| Oshi, SN | 1 |
| Alobu, I | 1 |
| Ukwaja, KN | 1 |
| Oshi, DC | 1 |
| Kumar, AK | 2 |
| Kannan, T | 2 |
| Kumar, SR | 3 |
| Banurekha, VV | 2 |
| Sekar, L | 2 |
| Ravichandran, N | 3 |
| Mathevan, G | 2 |
| Sanjeeva, GN | 2 |
| Dayal, R | 1 |
| Diacon, AH | 1 |
| Dawson, R | 1 |
| von Groote-Bidlingmaier, F | 1 |
| Symons, G | 1 |
| Venter, A | 1 |
| Donald, PR | 3 |
| van Niekerk, C | 1 |
| Everitt, D | 1 |
| Hutchings, J | 1 |
| Burger, DA | 1 |
| Schall, R | 1 |
| Mendel, CM | 1 |
| Honeyborne, I | 1 |
| Lipman, MC | 1 |
| Eckold, C | 1 |
| Evangelopoulos, D | 1 |
| Gillespie, SH | 1 |
| Pym, A | 3 |
| McHugh, TD | 1 |
| Grosset, J | 1 |
| Vernon, A | 2 |
| Acuña-Villaorduña, C | 1 |
| Ayakaka, I | 1 |
| Dryden-Peterson, S | 1 |
| Nakubulwa, S | 1 |
| Worodria, W | 1 |
| Reilly, N | 1 |
| Hosford, J | 1 |
| Fennelly, KP | 1 |
| Okwera, A | 3 |
| Jones-López, EC | 1 |
| van Oosterhout, JJ | 1 |
| Dzinjalamala, FK | 1 |
| Dimba, A | 1 |
| Waterhouse, D | 1 |
| Davies, G | 1 |
| Zijlstra, EE | 1 |
| Molyneux, ME | 1 |
| Molyneux, EM | 2 |
| Ward, S | 1 |
| Hennig, S | 1 |
| Naiker, S | 1 |
| Reddy, T | 1 |
| Egan, D | 1 |
| Kellerman, T | 1 |
| Owen, A | 1 |
| Meloni, M | 1 |
| Weber, R | 1 |
| Bekker, A | 1 |
| Draper, HR | 1 |
| van der Laan, L | 1 |
| Murray, S | 1 |
| McIlleron, HM | 1 |
| Sudha, V | 1 |
| Venkatesh, S | 1 |
| Kalpana, S | 1 |
| Agarwal, D | 1 |
| Velpandian, T | 1 |
| Singla, M | 1 |
| Kanhiya, K | 1 |
| Rockwood, N | 2 |
| Sogebi, OA | 1 |
| Adefuye, BO | 1 |
| Adebola, SO | 1 |
| Oladeji, SM | 1 |
| Adedeji, TO | 1 |
| Sirgel, F | 1 |
| Lesosky, M | 1 |
| Hlavsa, MC | 1 |
| Moonan, PK | 1 |
| Cowan, LS | 1 |
| Navin, TR | 1 |
| Kammerer, JS | 1 |
| Morlock, GP | 1 |
| Crawford, JT | 1 |
| Lobue, PA | 1 |
| Inge, LD | 1 |
| Wilson, JW | 1 |
| Cecchini, D | 1 |
| Ambrosioni, J | 1 |
| Brezzo, C | 1 |
| Corti, M | 1 |
| Rybko, A | 1 |
| Perez, M | 1 |
| Poggi, S | 1 |
| Ambroggi, M | 1 |
| Chideya, S | 1 |
| Winston, CA | 1 |
| Bradford, WZ | 2 |
| Hopewell, PC | 1 |
| Wells, CD | 1 |
| Reingold, AL | 3 |
| Kenyon, TA | 2 |
| Moeti, TL | 2 |
| Tappero, JW | 2 |
| Camacho, A | 1 |
| Pérez-Camacho, I | 1 |
| Rivero, A | 2 |
| Natera, C | 1 |
| García-Lázaro, M | 1 |
| Castón, JJ | 1 |
| Gallo, M | 1 |
| Kindelán, JM | 2 |
| Torre-Cisneros, J | 1 |
| Narendran, G | 1 |
| Venkatesan, P | 2 |
| Iliayas, S | 2 |
| Santhanakrishnan, R | 1 |
| Menon, PA | 1 |
| Padmapriyadarsini, C | 3 |
| Ramachandran, R | 1 |
| Chinnaiyan, P | 1 |
| Suhadev, M | 1 |
| Sakthivel, R | 1 |
| Narayanan, PR | 2 |
| Mahan, CS | 1 |
| Walusimbi, M | 1 |
| Johnson, DF | 1 |
| Lancioni, C | 1 |
| Charlebois, E | 1 |
| Baseke, J | 1 |
| Chervenak, KA | 1 |
| Mugerwa, RD | 3 |
| Havlir, DV | 1 |
| Mayanja-Kizza, H | 1 |
| Whalen, CC | 3 |
| Boom, WH | 1 |
| Gómez García, I | 1 |
| Gómez Mampaso, E | 1 |
| Burgos Revilla, J | 1 |
| Molina, MR | 1 |
| Sampietro Crespo, A | 1 |
| Buitrago, LA | 1 |
| Gómez Rodríguez, A | 1 |
| Baquero, F | 1 |
| Oxlade, O | 1 |
| Schwartzman, K | 1 |
| Pai, M | 1 |
| Heymann, J | 1 |
| Benedetti, A | 1 |
| Royce, S | 1 |
| Menzies, D | 1 |
| Leung, CC | 1 |
| Rieder, HL | 1 |
| Lange, C | 1 |
| Yew, WW | 1 |
| Wateba, MI | 1 |
| Diop, SA | 1 |
| Salou, M | 1 |
| Womitso, K | 1 |
| Nichols, S | 1 |
| Tidjani, O | 1 |
| Thee, S | 1 |
| Seddon, JA | 1 |
| Seifart, HI | 2 |
| Werely, CJ | 1 |
| Rosenkranz, B | 1 |
| Roll, S | 1 |
| Magdorf, K | 1 |
| Saleri, N | 1 |
| Dembélé, SM | 1 |
| Villani, P | 1 |
| Carvalho, AC | 1 |
| Cusato, M | 1 |
| Bonkoungou, V | 1 |
| Nacanabo, R | 1 |
| Kouanda, S | 1 |
| Comelli, M | 1 |
| Regazzi, M | 1 |
| Matteelli, A | 1 |
| Pascopella, L | 1 |
| Deriemer, K | 1 |
| Watt, JP | 1 |
| Flood, JM | 1 |
| Vahedi, M | 1 |
| Connolly, C | 1 |
| Rida, W | 1 |
| Onyebujoh, PC | 1 |
| Semvua, HH | 1 |
| Mtabho, CM | 1 |
| Fillekes, Q | 1 |
| van den Boogaard, J | 1 |
| Kisonga, RM | 1 |
| Mleoh, L | 1 |
| Ndaro, A | 1 |
| Kisanga, ER | 1 |
| van der Ven, A | 1 |
| Aarnoutse, RE | 1 |
| Kibiki, GS | 1 |
| Boeree, MJ | 1 |
| Burger, DM | 1 |
| Gandhi, NR | 1 |
| Moodley, P | 1 |
| Ramathal, M | 1 |
| Elson, I | 1 |
| Kreiswirth, BN | 1 |
| Mathema, B | 1 |
| Shashkina, E | 1 |
| Rothenberg, R | 1 |
| Moll, AP | 1 |
| Friedland, G | 1 |
| Sturm, AW | 1 |
| Shah, NS | 1 |
| Shaweno, D | 1 |
| Worku, A | 1 |
| Manosuthi, W | 1 |
| Sukasem, C | 1 |
| Lueangniyomkul, A | 1 |
| Mankatitham, W | 1 |
| Thongyen, S | 1 |
| Nilkamhang, S | 1 |
| Manosuthi, S | 1 |
| Sungkanuparph, S | 1 |
| Wanchu, A | 1 |
| Bhatnagar, A | 1 |
| Khullar, M | 1 |
| Sud, A | 1 |
| Bambery, P | 1 |
| Singh, S | 1 |
| Jasmer, RM | 1 |
| Daley, CL | 1 |
| Campos, PE | 1 |
| Suarez, PG | 1 |
| Sanchez, J | 1 |
| Zavala, D | 1 |
| Arevalo, J | 1 |
| Ticona, E | 1 |
| Nolan, CM | 1 |
| Hooton, TM | 1 |
| Holmes, KK | 1 |
| Perlman, DC | 1 |
| Segal, Y | 1 |
| Rosenkranz, S | 1 |
| Rainey, PM | 1 |
| Remmel, RP | 1 |
| Chirgwin, K | 1 |
| Salomon, N | 1 |
| Hafner, R | 2 |
| Texeira-Swiegelaar, C | 1 |
| Gordin, FM | 1 |
| Cohn, DL | 1 |
| Matts, JP | 2 |
| Chaisson, RE | 3 |
| O'Brien, RJ | 2 |
| Pedral-Sampaio, DB | 1 |
| Alves, CR | 1 |
| Netto, EM | 1 |
| Brites, C | 1 |
| Oliveira, AS | 1 |
| Badaro, R | 1 |
| Gurumurthy, P | 1 |
| Hemanth Kumar, AK | 1 |
| Rajasekaran, S | 1 |
| Bhagavathy, S | 1 |
| Mahilmaran, A | 1 |
| Paramesh, P | 1 |
| Ige, OM | 1 |
| Sogaolu, OM | 1 |
| Odaibo, GN | 1 |
| Olaleye, OD | 1 |
| Valencia Ortega, ME | 1 |
| Agerton, TB | 1 |
| Hopewell, P | 1 |
| Lockman, S | 1 |
| Oyewo, A | 1 |
| Talbot, EA | 1 |
| Moffat, HJ | 1 |
| Graham, SM | 1 |
| Bell, DJ | 1 |
| Nyirongo, S | 1 |
| Hartkoorn, R | 1 |
| Ward, SA | 1 |
| Gao, XF | 1 |
| Wang, L | 1 |
| Liu, GJ | 1 |
| Wen, J | 1 |
| Sun, X | 1 |
| Xie, Y | 1 |
| Li, YP | 1 |
| López-Cortés, L | 1 |
| Castillo, R | 1 |
| Verdejo, J | 1 |
| García, MA | 1 |
| Martínez-Marcos, FJ | 1 |
| Díez, F | 1 |
| Escribano, JC | 1 |
| Canueto, J | 1 |
| Lozano, F | 1 |
| Pasquau, J | 1 |
| Hernández, JJ | 1 |
| Márquez, M | 1 |
| Sukumar, B | 1 |
| Triveni, C | 1 |
| Gomathy, P | 1 |
| Thomas, B | 1 |
| Mathew, M | 1 |
| Angarano, G | 1 |
| Carbonara, D | 1 |
| Costa, D | 1 |
| Wada, M | 1 |
| Yamamoto, S | 1 |
| Ogata, H | 1 |
| Sugita, N | 1 |
| Kino, T | 1 |
| Hayashi, A | 1 |
| Nightingale, SL | 1 |
| Luo, C | 1 |
| Chintu, C | 1 |
| Bhat, G | 1 |
| Raviglione, M | 1 |
| Diwan, V | 1 |
| DuPont, HL | 1 |
| Zumla, A | 1 |
| Günthard, H | 1 |
| Fuhrer, HP | 1 |
| Pfyffer, GE | 1 |
| Ruef, C | 1 |
| Lüthy, R | 1 |
| Espinal, MA | 1 |
| Pérez, G | 1 |
| Camilo, E | 1 |
| Soto, S | 1 |
| Cruz, E | 1 |
| Matos, N | 1 |
| Gonzalez, G | 1 |
| Fisher, M | 1 |
| Tomlinson, DR | 1 |
| Coker, RJ | 1 |
| Nitta, AT | 1 |
| Burman, WJ | 2 |
| Brudney, KF | 1 |
| Miranda-Massari, JR | 1 |
| McGuinness, ME | 1 |
| Berning, SE | 2 |
| Gerena, GT | 1 |
| Schultsz, C | 1 |
| Kuijper, EJ | 1 |
| van Soolingen, D | 1 |
| Prins, JM | 1 |
| Colmenero, JD | 1 |
| García-Ordoñez, MA | 1 |
| Sebastián, MD | 1 |
| Pérez-Ruiz, E | 1 |
| Sánchez-Lora, J | 1 |
| Sánchez-González, J | 1 |
| Bentabol, G | 1 |
| Juárez, C | 1 |
| Sahai, J | 1 |
| Gallicano, K | 1 |
| Swick, L | 1 |
| Tailor, S | 1 |
| Garber, G | 1 |
| Seguin, I | 1 |
| Oliveras, L | 1 |
| Walker, S | 1 |
| Rachlis, A | 1 |
| Cameron, DW | 1 |
| Johnson, JL | 2 |
| Hom, DL | 2 |
| Huebner, R | 2 |
| Mugyenyi, P | 1 |
| Ellner, JJ | 2 |
| Halsey, NA | 1 |
| Coberly, JS | 1 |
| Desormeaux, J | 1 |
| Losikoff, P | 1 |
| Atkinson, J | 1 |
| Moulton, LH | 1 |
| Contave, M | 1 |
| Johnson, M | 1 |
| Davis, H | 1 |
| Geiter, L | 1 |
| Johnson, E | 1 |
| Boulos, R | 1 |
| Kimerling, ME | 1 |
| Phillips, P | 1 |
| Patterson, P | 1 |
| Hall, M | 1 |
| Robinson, CA | 1 |
| Dunlap, NE | 1 |
| Mbaye, PS | 1 |
| Talarmin, F | 1 |
| Sane, M | 1 |
| Eladari, D | 1 |
| Klotz, F | 1 |
| Martínez, E | 1 |
| Collazos, J | 1 |
| Mayo, J | 1 |
| Pozniak, AL | 1 |
| Ormerod, LP | 1 |
| Miller, R | 1 |
| Barker, J | 1 |
| Makatini, Z | 1 |
| Millard, J | 1 |
| Gordin, F | 1 |
| Miller, C | 1 |
| de Lourdes Garcia, M | 1 |
| Valdespino, JL | 1 |
| Coberly, J | 1 |
| Schechter, M | 1 |
| Klukowicz, AJ | 1 |
| Barry, MA | 1 |
| Gie, RP | 1 |
| van Rie, A | 1 |
| Quigley, MA | 1 |
| Mwinga, A | 2 |
| Hosp, M | 2 |
| Lisse, I | 1 |
| Fuchs, D | 1 |
| Godfrey-Faussett, P | 1 |
| James, JS | 1 |
| Mayanja, H | 1 |
| Mutuluuza Kityo, C | 1 |
| Nsubuga, P | 1 |
| Nakibali, JG | 1 |
| Loughlin, AM | 1 |
| Yun, H | 1 |
| Mugyenyi, PN | 1 |
| Zulu, I | 1 |
| Farthing, MJ | 1 |
| Mulambo, S | 1 |
| Kelly, P | 1 |
| Zhu, M | 1 |
| Starke, JR | 1 |
| Steiner, P | 1 |
| Stambaugh, JJ | 1 |
| Ashkin, D | 1 |
| Bulpitt, AE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes in HIV-tuberculosis Co-infected Ugandan Adults[NCT01782950] | Phase 4 | 400 participants (Anticipated) | Interventional | 2013-02-28 | Recruiting | ||
| A Randomised Open-Label Controlled Trial of a 4-Month Gatifloxacin-Containing Regimen Versus Standard Regimen for the Treatment of Adult Patients With Pulmonary Tuberculosis[NCT00216385] | Phase 3 | 2,070 participants | Interventional | 2005-01-31 | Recruiting | ||
| Culture Free Diagnosis and Follow-up of Multidrug Resistant Tuberculosis Patients[NCT03303963] | 3,356 participants (Actual) | Observational | 2017-05-04 | Completed | |||
| Plasma Drug Concentrations in the Treatment of Multidrug-resistant Tuberculosis in Relation to Minimum Inhibitory Concentrations - a Prospective Observational Study[NCT02816931] | 37 participants (Actual) | Observational | 2016-03-31 | Completed | |||
| An Open Label, Randomized Controlled Trial to Establish the Efficacy and Safety of a Study Strategy Consisting of 6 Months of Bedaquiline (BDQ), Delamanid (DLM), and Linezolid (LNZ), With Levofloxacin (LVX) and Clofazimine (CFZ) Compared to the Current So[NCT04062201] | Phase 3 | 402 participants (Actual) | Interventional | 2019-08-22 | Active, not recruiting | ||
| Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis[NCT03827811] | 625 participants (Anticipated) | Observational | 2020-01-30 | Recruiting | |||
| A Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of the Following: TMC207 Plus PA-824 Plus Pyrazinamide Plus Clofazimine, TMC207 Plus PA-824 Plus Pyrazinamide, TMC207 Plus PA-824 Plus Clofazimine Alone, TMC207 Plus Pyra[NCT01691534] | Phase 2 | 105 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in the Treatment of Tuberculosis Patient With HIV Infection in South Africa: A Phase II Trial[NCT00640887] | Phase 2 | 48 participants (Anticipated) | Interventional | 2009-02-28 | Completed | ||
| Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study)[NCT01637558] | Phase 4 | 200 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
| DNA Sequencing of MDR TB in Eastern Siberia[NCT02508610] | 630 participants (Anticipated) | Observational | 2013-11-30 | Recruiting | |||
| A Phase II Trial to Describe the Pharmacokinetics, Safety and Efficacy of Pharmacogenetics-guided Dosing of Isoniazid in Patients With HIV-associated TB[NCT05124678] | Phase 2 | 40 participants (Anticipated) | Interventional | 2021-12-07 | Recruiting | ||
| Randomized Clinical Trial to Assess the Efficacy of Short Course Intermittent Regimens for the Treatment of HIV-Associated Tuberculosis[NCT00376012] | Phase 3 | 300 participants (Actual) | Interventional | 2001-02-28 | Active, not recruiting | ||
| A Nurse Case Management Intervention to Improve MDR-TB/HIV Co-Infection Outcomes[NCT02129244] | 3,600 participants (Anticipated) | Interventional | 2014-10-31 | Active, not recruiting | |||
| A Pharmacokinetics Study Comparing Lopinavir Plasma Exposure When Given as Lopinavir/Ritonavir (1:1) in the Presence of Rifampicin and Lopinavir/Ritonavir (4:1) Without Rifampicin in HIV and TB Co-infected Children in South Africa.[NCT02348177] | Phase 4 | 96 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| Pharmacokinetics of Antituberculosis Agents in HIV-Infected Persons With Tuberculosis[NCT00000950] | 50 participants | Interventional | Completed | ||||
| Immune Activation and Drug Absorption in HIV-Infected Patients[NCT01845298] | 7 participants (Actual) | Interventional | 2014-06-30 | Completed | |||
| Pharmacokinetics and Pharmacodynamics of High Versus Standard Dose Rifampicin in Patients With Pulmonary Tuberculosis in the Kilimanjaro Region, Tanzania.[NCT00760149] | Phase 2 | 150 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| A Randomized, Four-arm Open Label Phase Two-b Clinical Trial to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of High Dose Rifampicin in TB-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy[NCT03982277] | Phase 2 | 130 participants (Actual) | Interventional | 2019-04-30 | Completed | ||
| Evaluation of Two Different Preventive Therapy Regimens for Tuberculosis in HIV Infected Persons[NCT00351702] | Phase 3 | 650 participants (Actual) | Interventional | 2001-02-28 | Completed | ||
| URBAN ARCH (3/5) Uganda Cohort TB Preventive Therapy for HIV-infected Alcohol Users in Uganda: an Evaluation of Safety Tolerability and Adherence[NCT03302299] | Phase 4 | 302 participants (Actual) | Interventional | 2017-04-07 | Completed | ||
| Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection[NCT00000638] | 2,000 participants | Interventional | Completed | ||||
| Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection[NCT00000636] | 2,000 participants | Interventional | Completed | ||||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01691534)
Timeframe: 14 consecutive days of treatment
| Intervention | log10CFU/ml/day (Mean) |
|---|---|
| TMC207, PA-824, Pyrazinamide and Clofazimine (J-PA-Z-C) | 0.115 |
| TMC207, PA-824 and Pyrazinamide (J-PA-Z) | 0.167 |
| TMC207, PA-824 and Clofazimine (J-PA-C) | 0.076 |
| TMC207, Pyrazinamide and Clofazimine (J-Z-C) | 0.124 |
| Pyrazinamide (Z) | 0.036 |
| Clofazimine (C) | -0.017 |
| Rifafour | 0.151 |
(NCT01691534)
Timeframe: Days 0-14
| Intervention | percentage of change in time/day (Mean) |
|---|---|
| TMC207, PA-824, Pyrazinamide and Clofazimine (J-PA-Z-C) | 6.3 |
| TMC207, PA-824 and Pyrazinamide (J-PA-Z) | 7.0 |
| TMC207, PA-824 and Clofazimine (J-PA-C) | 4.3 |
| TMC207, Pyrazinamide and Clofazimine (J-Z-C) | 4.9 |
| Pyrazinamide (Z) | 2.0 |
| Clofazimine (C) | -0.3 |
| Rifafour | 6.3 |
(NCT01691534)
Timeframe: Day 0-2
| Intervention | percentage of change in time/day (Mean) |
|---|---|
| TMC207, PA-824, Pyrazinamide and Clofazimine (J-PA-Z-C) | 10.6 |
| TMC207, PA-824 and Pyrazinamide (J-PA-Z) | 13.2 |
| TMC207, PA-824 and Clofazimine (J-PA-C) | 6.0 |
| TMC207, Pyrazinamide and Clofazimine (J-Z-C) | 9.1 |
| Pyrazinamide (Z) | 4.7 |
| Clofazimine (C) | 2.1 |
| Rifafour | 12.9 |
(NCT01691534)
Timeframe: Days 7-14
| Intervention | percentage of change in time/day (Mean) |
|---|---|
| TMC207, PA-824, Pyrazinamide and Clofazimine (J-PA-Z-C) | 3.6 |
| TMC207, PA-824 and Pyrazinamide (J-PA-Z) | 4.5 |
| TMC207, PA-824 and Clofazimine (J-PA-C) | 3.1 |
| TMC207, Pyrazinamide and Clofazimine (J-Z-C) | 3.0 |
| Pyrazinamide (Z) | 0.8 |
| Clofazimine (C) | -1.3 |
| Rifafour | 4.4 |
(NCT01691534)
Timeframe: Days 0-2
| Intervention | log10CFU/ml/day (Mean) |
|---|---|
| TMC207, PA-824, Pyrazinamide and Clofazimine (J-PA-Z-C) | 0.161 |
| TMC207, PA-824 and Pyrazinamide (J-PA-Z) | 0.196 |
| TMC207, PA-824 and Clofazimine (J-PA-C) | 0.062 |
| TMC207, Pyrazinamide and Clofazimine (J-Z-C) | 0.132 |
| Pyrazinamide (Z) | 0.080 |
| Clofazimine (C) | 0.018 |
| Rifafour | 0.141 |
(NCT01691534)
Timeframe: Day 7-14
| Intervention | log10CFU/ml/day (Mean) |
|---|---|
| TMC207, PA-824, Pyrazinamide and Clofazimine (J-PA-Z-C) | 0.085 |
| TMC207, PA-824 and Pyrazinamide (J-PA-Z) | 0.146 |
| TMC207, PA-824 and Clofazimine (J-PA-C) | 0.085 |
| TMC207, Pyrazinamide and Clofazimine (J-Z-C) | 0.118 |
| Pyrazinamide (Z) | 0.022 |
| Clofazimine (C) | -0.038 |
| Rifafour | 0.157 |
Safety will be assessed by the occurrence of a Grade 3/4 hepatotoxicity at any time during the assigned treatment period. (NCT03302299)
Timeframe: Hepatotoxicity occurring during the six month course (180 pills) of isoniazid (INH), which may be taken over a maximum of 9 months.
| Intervention | percent (Number) |
|---|---|
| INH and Vitamin B6 | 8.3 |
Lack of tolerability will be defined as any isoniazid (INH) treatment discontinuation prior to completion of the prescribed course (6 months of INH taken over a maximum period of 9 months) due to side effects or alanine transaminase (ALT)/aspartate transaminase (AST) elevations. (NCT03302299)
Timeframe: Six month course (180 pills) of isoniazid (INH), which may be taken over a maximum of 9 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| INH and Vitamin B6 | 32 |
Alanine transaminase (ALT) or aspartate transaminase (AST) elevations (>2x the upper limit of normal) at study screening (NCT03302299)
Timeframe: Study screening visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Screening | 80 |
Latent tuberculosis assessed at screening via tuberculin skin testing (TST). A TST induration >=5mm was considered positive for latent tuberculosis. (NCT03302299)
Timeframe: Study screening visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Screening | 308 |
INH concentration in hair (pmol/mg) will be measured at 3- and 6- months during INH therapy. (NCT03302299)
Timeframe: Measured at 3- and 6- months after INH initiation
| Intervention | pmol/mg (Median) | |
|---|---|---|
| at 3 months | at 6 months | |
| INH and Vitamin B6 | 36.0 | 37.8 |
Suboptimal INH adherence was defined as <90% of days with at least 1 electronic medication management (EMM) pill cap opening in the previous 90 days, at 3- and 6-months. (NCT03302299)
Timeframe: Adherence will be measured over the 6 months on INH or until INH discontinuation (whichever is shorter)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| at 3 months | at 6 months | |
| INH and Vitamin B6 | 31.3 | 43.9 |
"Participants were asked In the past 30 days, how many days in total have you not taken your pill? and were presented with a visual analog scale (VAS) to indicate the percentage of INH taken in the past 30 days. We converted the VAS percentage into number of days out of 30 to match the first question. Our final self-report measure was the minimum number of the 2 self-reported measurements." (NCT03302299)
Timeframe: Self-reported INH medication adherence via VAS will be measured 3- and 6- months after starting INH
| Intervention | days (Median) | |
|---|---|---|
| at 3 months | at 6 months | |
| INH and Vitamin B6 | 30 | 30 |
The Self Rating Single Item (SRSI) adherence scale asks participants to rate their ability to take their medications as prescribed over the past 30 days. Participants reporting INH use in the prior 30 days at the 3- or 6-month interview are included here, and reported their INH adherence in the prior 30 days as excellent, very good, good, fair, poor, or very poor. (NCT03302299)
Timeframe: Self-reported INH medication adherence via SRSI will be measured 3- and 6- months after starting INH
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| At 3 months72558043 | At 6 months72558043 | |||||||||||
| Excellent | Very good | Good | Fair | Poor | Very poor | |||||||
| INH and Vitamin B6 | 160 | |||||||||||
| INH and Vitamin B6 | 79 | |||||||||||
| INH and Vitamin B6 | 38 | |||||||||||
| INH and Vitamin B6 | 2 | |||||||||||
| INH and Vitamin B6 | 124 | |||||||||||
| INH and Vitamin B6 | 90 | |||||||||||
| INH and Vitamin B6 | 41 | |||||||||||
| INH and Vitamin B6 | 4 | |||||||||||
| INH and Vitamin B6 | 0 | |||||||||||
| INH and Vitamin B6 | 1 | |||||||||||
11 reviews available for pyrazinamide and HIV Coinfection
| Article | Year |
|---|---|
Evidence for Implementation: Management of TB in HIV and Pregnancy.
Topics: Antitubercular Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmiss | 2022 |
Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Ethambutol; HIV; HIV Infections; Humans; Isoniazid; | 2023 |
Are We There Yet? Short-Course Regimens in TB and HIV: From Prevention to Treatment of Latent to XDR TB.
Topics: Anti-HIV Agents; Antitubercular Agents; Drug Interactions; Extensively Drug-Resistant Tuberculosis; | 2020 |
Pharmacokinetics of First-Line Anti-Tubercular Drugs.
Topics: Age Factors; Antitubercular Agents; Child; Drug Overdose; Ethambutol; Food; Genotype; HIV Infections | 2019 |
Severe disseminated tuberculosis in HIV-negative refugees.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Ethambutol; Fluorine Radioisotopes; HIV Infections; | 2019 |
Understanding pharmacokinetics to improve tuberculosis treatment outcome.
Topics: Antitubercular Agents; Diabetes Mellitus; Drug Monitoring; Ethambutol; HIV Infections; Humans; Isoni | 2014 |
[Use of rifampicin plus pyrazinamide for antituberculosis prophylaxis does not increase the risk of severe hepatotoxicity in HIV patients: meta-analysis of randomized controlled clinical trials].
Topics: Anti-HIV Agents; Antibiotic Prophylaxis; Antitubercular Agents; Chemical and Drug Induced Liver Inju | 2010 |
Tuberculous orchiepididymitis during 1978-2003 period: review of 34 cases and role of 16S rRNA amplification.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Combined Modality Therapy; Comorbidity; Epidi | 2010 |
Treatment of latent infection with Mycobacterium tuberculosis: update 2010.
Topics: Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Communicable Disease Control; Drug | 2011 |
Rifampin and pyrazinamide for treatment of latent tuberculosis infection: is it safe?
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Cos | 2003 |
Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Comorbidity; Drug Therapy, Combination; HIV Infe | 2006 |
25 trials available for pyrazinamide and HIV Coinfection
| Article | Year |
|---|---|
Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.
Topics: Adult; Antitubercular Agents; Area Under Curve; Coinfection; Drug Administration Schedule; Drug Dosa | 2013 |
Impact of tuberculosis treatment on CD4 cell count, HIV RNA, and p24 antigen in patients with HIV and tuberculosis.
Topics: Adult; Antitubercular Agents; Biomarkers; CD4 Lymphocyte Count; Coinfection; Dietary Supplements; Dr | 2013 |
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Disinfection; Drug Antagonism; Drug Syne | 2015 |
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Disinfection; Drug Antagonism; Drug Syne | 2015 |
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Disinfection; Drug Antagonism; Drug Syne | 2015 |
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Disinfection; Drug Antagonism; Drug Syne | 2015 |
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Disinfection; Drug Antagonism; Drug Syne | 2015 |
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Disinfection; Drug Antagonism; Drug Syne | 2015 |
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Disinfection; Drug Antagonism; Drug Syne | 2015 |
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Disinfection; Drug Antagonism; Drug Syne | 2015 |
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Disinfection; Drug Antagonism; Drug Syne | 2015 |
Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Female; HIV Infections; Humans; India; I | 2015 |
Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.
Topics: Adult; Antitubercular Agents; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Female; HIV | 2015 |
Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.
Topics: Adult; Antitubercular Agents; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Female; HIV | 2015 |
Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.
Topics: Adult; Antitubercular Agents; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Female; HIV | 2015 |
Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.
Topics: Adult; Antitubercular Agents; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Female; HIV | 2015 |
Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi.
Topics: Adolescent; Adult; Antitubercular Agents; Ethambutol; Female; HIV Infections; Humans; Isoniazid; Mal | 2015 |
Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis.
Topics: Adult; Antitubercular Agents; Area Under Curve; CD4 Lymphocyte Count; Coinfection; Ethambutol; Femal | 2016 |
Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines.
Topics: Anti-Bacterial Agents; Area Under Curve; Coinfection; Drug Dosage Calculations; Ethambutol; Female; | 2016 |
Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2010 |
Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2010 |
Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2010 |
Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2010 |
Tuberculosis treatment in HIV infected Ugandans with CD4 counts>350 cells/mm reduces immune activation with no effect on HIV load or CD4 count.
Topics: Adult; Antitubercular Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymph | 2010 |
Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.
Topics: Antitubercular Agents; Area Under Curve; Child, Preschool; Coinfection; Female; HIV Infections; Huma | 2011 |
Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Deoxyc | 2013 |
The short-term effects of anti-tuberculosis therapy on plasma pyridoxine levels in patients with pulmonary tuberculosis.
Topics: Adult; Antitubercular Agents; Ethambutol; Female; Follow-Up Studies; HIV Infections; Humans; Isoniaz | 2004 |
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
Topics: Acetylation; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Eth | 2004 |
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
Topics: Acetylation; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Eth | 2004 |
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
Topics: Acetylation; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Eth | 2004 |
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
Topics: Acetylation; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Eth | 2004 |
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
Topics: Acetylation; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Eth | 2004 |
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
Topics: Acetylation; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Eth | 2004 |
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
Topics: Acetylation; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Eth | 2004 |
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
Topics: Acetylation; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Eth | 2004 |
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
Topics: Acetylation; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Eth | 2004 |
Evaluation of modified short course chemotherapy in active pulmonary tuberculosis patients with human immunodeficiency virus infection in University College Hospital, Ibadan, Nigeria--a preliminary report.
Topics: Acne Vulgaris; Adolescent; Adult; Age Distribution; Aged; Antitubercular Agents; Drug Therapy, Combi | 2004 |
[Randomized clinical trial investigating three chemoprophylaxis regimens for latent tuberculosis infection in HIV-infected patients].
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Isoniazid; | 2007 |
Nutritional status of persons with HIV infection, persons with HIV infection and tuberculosis, and HIV-negative individuals from southern India.
Topics: Adult; AIDS-Related Opportunistic Infections; Anemia; Antitubercular Agents; Body Composition; Drug | 2008 |
Low antituberculosis drug concentrations in patients with AIDS.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona | 1996 |
Low antituberculosis drug concentrations in patients with AIDS.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona | 1996 |
Low antituberculosis drug concentrations in patients with AIDS.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona | 1996 |
Low antituberculosis drug concentrations in patients with AIDS.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona | 1996 |
Low antituberculosis drug concentrations in patients with AIDS.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona | 1996 |
Low antituberculosis drug concentrations in patients with AIDS.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona | 1996 |
Low antituberculosis drug concentrations in patients with AIDS.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona | 1996 |
Low antituberculosis drug concentrations in patients with AIDS.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona | 1996 |
Low antituberculosis drug concentrations in patients with AIDS.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona | 1996 |
[Compliance, efficacy and tolerability of the therapeutic regimen recommended by National Consensus on Tuberculosis].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antitubercular Agents; Child; Chi | 1997 |
A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Therapy, Combination; Fema | 1997 |
A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Therapy, Combination; Fema | 1997 |
A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Therapy, Combination; Fema | 1997 |
A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Therapy, Combination; Fema | 1997 |
Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; F | 1998 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Cohort St | 2001 |
Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Therapy, Combi | 2001 |
Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis.
Topics: Adult; Aging; Antitubercular Agents; Area Under Curve; Child; Chromatography, Gas; Drug Monitoring; | 2002 |
71 other studies available for pyrazinamide and HIV Coinfection
| Article | Year |
|---|---|
No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients.
Topics: Adult; Antitubercular Agents; Ethambutol; HIV Infections; Humans; Isoniazid; Pyrazinamide; Rifampin; | 2022 |
Diagnostic Accuracy of Therapeutic Drug Monitoring During Tuberculosis Treatment.
Topics: Antitubercular Agents; Drug Monitoring; Ethambutol; HIV Infections; Humans; Isoniazid; Pyrazinamide; | 2022 |
IFN-γ ELISpot in Severe Cutaneous Adverse Reactions to First-Line Antituberculosis Drugs in an HIV Endemic Setting.
Topics: Antitubercular Agents; Ethambutol; HIV Infections; Humans; Interferon-gamma; Isoniazid; Pyrazinamide | 2022 |
Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Female; HIV; HIV Infections; Huma | 2023 |
Effect of HIV infection on plasma exposure to first-line TB drugs and target attainment in children.
Topics: Antitubercular Agents; Child; Child, Preschool; Coinfection; HIV Infections; Humans; Isoniazid; Pyra | 2023 |
Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus-associated tuberculosis.
Topics: Adult; Antitubercular Agents; Female; HIV; HIV Infections; Humans; Isoniazid; Male; Pyrazinamide; Tu | 2020 |
Primary breast tuberculosis in an HIV-infected patient.
Topics: Adult; Antitubercular Agents; Biopsy; Breast; Ethambutol; Female; HIV Infections; Humans; Isoniazid; | 2020 |
Factors Affecting the Pharmacokinetics of Pyrazinamide and Its Metabolites in Patients Coinfected with HIV and Implications for Individualized Dosing.
Topics: Antitubercular Agents; Coinfection; Female; HIV Infections; Humans; Male; Pyrazinamide; Tuberculosis | 2021 |
Poncet's disease in human immunodeficiency virus: a case report.
Topics: Adult; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Arthritis, Reactive; Etha | 2017 |
Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Drug Combinations; Ethambutol; HIV Infections | 2017 |
Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study.
Topics: Adult; Anti-Retroviral Agents; Antitubercular Agents; Biomedical Research; CD4 Lymphocyte Count; Coh | 2017 |
Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.
Topics: Adult; Age Distribution; Aged; Alcohol Drinking; Aminosalicylic Acid; Antitubercular Agents; Cohort | 2017 |
Pyrazinamide clearance is impaired among HIV/tuberculosis patients with high levels of systemic immune activation.
Topics: Anti-HIV Agents; Antitubercular Agents; HIV Infections; Humans; Pyrazinamide; Tuberculosis | 2017 |
Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.
Topics: Anti-HIV Agents; Antitubercular Agents; Child; Drug Administration Schedule; Drug Combinations; Drug | 2018 |
A retrospective study on tuberculosis treatment outcomes at Jinka General Hospital, southern Ethiopia.
Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Drug Combinations; Ethambutol; Ethiopia; Fema | 2017 |
Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications.
Topics: Adolescent; Age Factors; Antitubercular Agents; Body Weight; Child; Child, Preschool; Coinfection; D | 2018 |
Treatment outcomes and tolerability of the revised WHO anti-tuberculosis drug dosages for children.
Topics: Antitubercular Agents; Child, Preschool; Cohort Studies; Female; HIV Infections; Humans; Infant; Inf | 2018 |
Tuberculosis treatment outcome and predictors in northern Ethiopian prisons: a five-year retrospective analysis.
Topics: Adolescent; Adult; Aftercare; Anti-Retroviral Agents; Antitubercular Agents; Coinfection; Directly O | 2018 |
Drug-resistance patterns of Mycobacterium tuberculosis strains and associated risk factors among multi drug-resistant tuberculosis suspected patients from Ethiopia.
Topics: Antitubercular Agents; Ethambutol; Ethiopia; Female; HIV Infections; Humans; Isoniazid; Male; Mycoba | 2018 |
Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study.
Topics: Adult; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Resistance, Multiple, Bacterial; E | 2019 |
Potentially High Number of Ineffective Drugs with the Standard Shorter Course Regimen for Multidrug-Resistant Tuberculosis Treatment in Haiti.
Topics: Adult; Antitubercular Agents; Coinfection; Drug Resistance, Multiple, Bacterial; Ethambutol; Ethiona | 2019 |
Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection.
Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Cycloserine; Drug Therapy, Combination; Etham | 2013 |
High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses.
Topics: Adolescent; Adult; Aged; Body Mass Index; Body Weight; Clofazimine; Dose-Response Relationship, Drug | 2014 |
Investigating gender disparities in the profile and treatment outcomes of tuberculosis in Ebonyi state, Nigeria.
Topics: Adult; Antitubercular Agents; Cohort Studies; Coinfection; Ethambutol; Female; Health Status Dispari | 2015 |
Effective anti-tuberculosis therapy correlates with plasma small RNA.
Topics: Adult; Antitubercular Agents; Biomarkers; Coinfection; Ethambutol; Female; Gene Expression Profiling | 2015 |
A reader's guide to the bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.
Topics: Clofazimine; Diarylquinolines; Female; HIV Infections; Humans; Male; Nitroimidazoles; Pyrazinamide; | 2015 |
High mortality associated with retreatment of tuberculosis in a clinic in Kampala, Uganda: a retrospective study.
Topics: Adult; Antitubercular Agents; Coinfection; Ethambutol; Female; Follow-Up Studies; HIV Infections; Hu | 2015 |
Cure of tuberculosis despite serum concentrations of antituberculosis drugs below published reference ranges.
Topics: Adult; Aged; Antitubercular Agents; Drug Monitoring; Female; HIV Infections; Humans; Isoniazid; Line | 2015 |
Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status.
Topics: Antitubercular Agents; Child; Child, Preschool; Chromatography, High Pressure Liquid; Female; Follow | 2016 |
Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
Topics: Adolescent; Age Factors; Antitubercular Agents; Child; Child, Preschool; Chromatography, Liquid; Coi | 2016 |
HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Area Under Cur | 2016 |
Clinical predictors of aminoglycoside-induced ototoxicity in drug-resistant Tuberculosis patients on intensive therapy.
Topics: Adult; Age Factors; Aminoglycosides; Antitubercular Agents; Audiometry, Pure-Tone; Body Mass Index; | 2017 |
Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis.
Topics: Adult; Antitubercular Agents; Coinfection; Drug Interactions; Drug Therapy, Combination; Female; HIV | 2017 |
Human tuberculosis due to Mycobacterium bovis in the United States, 1995-2005.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Bacterial Agents; Child; Child, Presch | 2008 |
Update on the treatment of tuberculosis.
Topics: Antitubercular Agents; Comorbidity; Directly Observed Therapy; Disease Progression; Drug Therapy, Co | 2008 |
Tuberculous meningitis in HIV-infected and non-infected patients: comparison of cerebrospinal fluid findings.
Topics: Adult; Antitubercular Agents; Cerebrospinal Fluid; Cerebrospinal Fluid Proteins; Drug Resistance, Mu | 2009 |
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Botswana; CD4 Lymphocyte Count; E | 2009 |
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Botswana; CD4 Lymphocyte Count; E | 2009 |
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Botswana; CD4 Lymphocyte Count; E | 2009 |
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Botswana; CD4 Lymphocyte Count; E | 2009 |
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Botswana; CD4 Lymphocyte Count; E | 2009 |
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Botswana; CD4 Lymphocyte Count; E | 2009 |
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Botswana; CD4 Lymphocyte Count; E | 2009 |
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Botswana; CD4 Lymphocyte Count; E | 2009 |
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Botswana; CD4 Lymphocyte Count; E | 2009 |
Predicting outcomes and drug resistance with standardised treatment of active tuberculosis.
Topics: Cohort Studies; Communicable Disease Control; Drug Resistance, Bacterial; Global Health; HIV Infecti | 2010 |
[Sputum smear conversion during intensive TB treatment phase according to HIV status, in hospitalised patients in Togo].
Topics: Adult; Antitubercular Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Ethambutol; Female; F | 2011 |
Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Burkina Faso; | 2012 |
When tuberculosis comes back: who develops recurrent tuberculosis in california?
Topics: Adult; Antitubercular Agents; California; Drug Therapy, Combination; Female; HIV; HIV Infections; Hu | 2011 |
Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines.
Topics: Adolescent; Adult; Age Factors; Aged; Antitubercular Agents; Birth Weight; Drug Resistance, Multiple | 2012 |
Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines.
Topics: Adolescent; Adult; Age Factors; Aged; Antitubercular Agents; Birth Weight; Drug Resistance, Multiple | 2012 |
Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines.
Topics: Adolescent; Adult; Age Factors; Aged; Antitubercular Agents; Birth Weight; Drug Resistance, Multiple | 2012 |
Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines.
Topics: Adolescent; Adult; Age Factors; Aged; Antitubercular Agents; Birth Weight; Drug Resistance, Multiple | 2012 |
Nosocomial transmission of extensively drug-resistant tuberculosis in a rural hospital in South Africa.
Topics: Adult; Antitubercular Agents; Cluster Analysis; Cross Infection; Drug Therapy, Combination; Ethambut | 2013 |
Tuberculosis treatment survival of HIV positive TB patients on directly observed treatment short-course in Southern Ethiopia: a retrospective cohort study.
Topics: Adult; Anti-Retroviral Agents; Antitubercular Agents; Coinfection; Drug Administration Schedule; Fem | 2012 |
Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Aryl Hydrocarbon Hydrox | 2013 |
Antitubercular therapy decreases nitric oxide production in HIV/TB coinfected patients.
Topics: Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biomarkers; CD4 Lymphocyte Count; CD4-Pos | 2002 |
Multidrug-resistant Mycobacterium tuberculosis in HIV-infected persons, Peru.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Drug Resistance, Multiple, Bacter | 2003 |
The clinical pharmacokinetics of pyrazinamide in HIV-infected persons with tuberculosis.
Topics: Adult; Age Distribution; Antitubercular Agents; Area Under Curve; Female; HIV Infections; Humans; Ma | 2004 |
Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?
Topics: Adolescent; Adult; Aspartate Aminotransferases; Bilirubin; Chemical and Drug Induced Liver Injury; D | 2004 |
Efficacy and safety of Efavirenz in HIV patients on Rifampin for tuberculosis.
Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; | 2004 |
[Medicine and television: a diagnosis history].
Topics: Adult; Antitubercular Agents; Cholestasis, Intrahepatic; Diagnostic Errors; Hepatitis B; Hepatitis C | 2005 |
Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana.
Topics: Adult; Antitubercular Agents; Botswana; Comorbidity; Ethambutol; Female; HIV Infections; Humans; Iso | 2005 |
Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection.
Topics: Adolescent; Adult; Age Factors; Child; Child, Preschool; Ethambutol; HIV Infections; Humans; Infant; | 2006 |
Drug resistance of Mycobacterium tuberculosis strains isolated from HIV-infected Italian patients: preliminary report from a multicentric study. The Italian Tuberculosis Drug Resistance Study Group.
Topics: Antitubercular Agents; Drug Resistance, Microbial; Ethambutol; HIV Infections; Humans; Isoniazid; It | 1995 |
[Two pulmonary tuberculosis cases with HIV infection].
Topics: Adult; Female; HIV Infections; Humans; Isoniazid; Male; Pyrazinamide; Rifampin; Streptomycin; Tuberc | 1994 |
From the Food and Drug Administration.
Topics: Antitubercular Agents; Blood Donors; Drug Approval; Drug Combinations; Electromagnetic Phenomena; Eq | 1994 |
Human immunodeficiency virus type-1 infection in Zambian children with tuberculosis: changing seroprevalence and evaluation of a thioacetazone-free regimen.
Topics: Adolescent; Child; Child, Preschool; Drug Hypersensitivity; Drug Therapy, Combination; Female; HIV I | 1994 |
[Disseminated tuberculosis with a multiresistant strain of Mycobacterium tuberculosis in an HIV-infected Swiss male].
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Resistance, Microbial; Dru | 1993 |
Human immunodeficiency virus infection in children with tuberculosis in Santo Domingo, Dominican Republic: prevalence, clinical findings, and response to antituberculosis treatment.
Topics: AIDS Serodiagnosis; Antibiotics, Antitubercular; Antitubercular Agents; Child, Preschool; Dominican | 1996 |
The management of mycobacterial infections in HIV seropositive individuals. Jefferiss Wing Therapeutics and Protocols Group.
Topics: Adrenal Cortex Hormones; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitu | 1996 |
Disseminated infection due to multidrug-resistant Mycobacterium bovis in a patient who was seropositive for human immunodeficiency virus.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; DNA Fingerprinting; DNA, Bacterial; Drug Resista | 1996 |
Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection.
Topics: Adult; Aged; Antitubercular Agents; Case-Control Studies; Diarrhea; Ethambutol; Female; HIV Infectio | 1997 |
Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients.
Topics: Adult; Aged; Antibiotics, Antitubercular; Antitubercular Agents; Drug Monitoring; Drug Therapy, Comb | 1998 |
[Fulminant hepatitis in the course of antitubercular treatment (apropos of 2 cases)].
Topics: Adult; Anti-Bacterial Agents; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Th | 1995 |
Shock and cerebral infarct after rifampin re-exposure in a patient infected with human immunodeficiency virus.
Topics: Adult; Anaphylaxis; Antibiotics, Antitubercular; Antitubercular Agents; Cerebral Infarction; Drug Hy | 1998 |
Reply: Treatment of tuberculosis in HIV-infected patients.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Drug Therapy, Combination; HIV Infections; Human | 1999 |
Reply to Davis and colleagues: Twice weekly, directly observed treatment for HIV-infected and uninfected tuberculosis patients: cohort study in rural South Africa.
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Microbial; Drug Resistance, Mu | 1999 |
Second episode of tuberculosis in an HIV-infected child: relapse or reinfection?
Topics: AIDS-Related Opportunistic Infections; Amoxicillin-Potassium Clavulanate Combination; Antibiotics, A | 2000 |
Medical advances with international impact.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antibiotics, Antitubercular; Antitubercular | 1998 |
New TB therapy works for HIV-positive patients.
Topics: Antitubercular Agents; Clinical Trials as Topic; Disease Progression; HIV Infections; Humans; Isonia | 1998 |
Tuberculosis preventative treatment also prevented diarrhoea in HIV-infected patients in Zambia.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Diarrhea; Drug Therapy, Combination; Follow-Up S | 2002 |